Compare OLB & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLB | IMRN |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 6.2M |
| IPO Year | 2019 | 2016 |
| Metric | OLB | IMRN |
|---|---|---|
| Price | $0.54 | $0.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 421.6K | 20.3K |
| Earning Date | 05-14-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,838,988.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $0.68 |
| 52 Week High | $2.50 | $2.38 |
| Indicator | OLB | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 53.56 |
| Support Level | $0.31 | $0.69 |
| Resistance Level | $0.71 | $0.89 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 33.64 | 56.61 |
The OLB Group Inc is a diversified fintech e-commerce merchant services provider and Bitcoin crypto mining enterprise. It focuses on a suite of products in the merchant services marketplace and seeks to provide integrated business solutions to merchants throughout the United States. Along with its subsidiaries, the company offers a cloud-based business management platform that provides turnkey solutions for merchants to enable them to build and manage their retail businesses, whether online or at a brick-and-mortar location, payment processing solutions, payment gateway, virtual terminal with proprietary business management tools, and crowdfunding solutions. The company has two business segments; Fintech Services which generates key revenue, and the Bitcoin Mining business segment.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.